Zyprexa Payors' Off-Label Suit Denied By High Court

Law360, New York (June 27, 2011, 5:16 PM EDT) -- The U.S. Supreme Court on Monday denied a request by a class of insurers, labor unions and pension funds that they be allowed to sue Eli Lilly & Co. over the company's alleged off-label and fraudulent marketing of its antipsychotic Zyprexa.

The group of plaintiffs sought to overturn a Second Circuit decision that effectively blocked them from pursuing claims against Eli Lilly related to its marketing of Zyprexa.

In a petition for a writ of certiorari filed March 25, the plaintiffs argued that private insurers should be able...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.